Investigating the Anabolic Response to Resistance Exercise After Critical Illness (ARTIST-2) (ARTIST-2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT05261984

Recruitment Status : Recruiting

First Posted : March 2, 2022

Last Update Posted : June 3, 2022

See Contacts and Locations

Sponsor:

Information provided by (Responsible Party):

Martin Sundstrom Rehal, Karolinska University Hospital

Study Description

Brief Summary:

ICU survivors often suffer from long-term functional disability. An attenuated response to physical exercise in skeletal muscle after critical illness may contribute to persisting weakness.

The aim of this study is to investigate the effects of resistance exercise on muscle protein synthesis in former ICU patients. The investigators hypothesize that study subjects recovering from critical illness have an impaired anabolic response to resistance exercise after ICU stay as compared to non-critically ill controls.

Condition or disease	Intervention/treatment	Phase
Critical Illness Muscle Loss	Procedure: Resistance exercise Dietary Supplement: Oral protein supplementation	Not Applicable

Detailed Description:

Background

The debilitating impact of critical illness has been recognized for several decades. Disability related to intensive care is now described as a syndrome called ICU-acquired weakness (ICUAW). ICUAW affects up to 70% of ICU patients and is most common with higher illness severity. Patients that develop ICUAW require longer hospitalization and have a higher risk of death. Weakness may persists for several years in ICU survivors. It has significant long-term consequences, and is associated with increased health care costs, delayed return to work, and overall poor quality of life.

Muscle atrophy is a major contributor to ICUAW. Critical illness is associated with a rapid loss of skeletal muscle, induced by catabolic signals from proinflammatory cytokines and hormones. The ability to regain lost muscle mass during convalescence may also be impaired. In a small observational study, muscle atrophy resolved only in a minority of ICU survivors at six months after ICU discharge.

Studies in exercise physiology have demonstrated that resistance training and amino acid ingestion have synergistic effects on muscle protein synthesis in healthy subjects. It is therefore an appealing therapy to reconstitute muscle mass after critical illness. Despite several clinical trials, there is equipoise regarding the efficacy of exercise in improving physical function in-ICU after ICU discharge. These mixed signals are unsurprising given the heterogeneous causes of ICUAW.

Only a few studies in this field have examined muscle architecture or cellular signaling in response to training. However, the gold standard in determining the anabolic response to exercise is to directly measure the effects on protein synthesis and breakdown. There is still no published research using this methodology to assess the effects of exercise interventions in former ICU patients. To understand the role of physical exercise in regaining lost muscle mass, the investigators plan to investigate the anabolic effects to resistance training after critical illness.

Aim and hypothesis

The aim of this study is to determine the anabolic response to resistance exercise after critical illness. The investigators hypothesize that study subjects recovering from critical illness have an impaired anabolic response to resistance exercise after ICU stay as compared to non-critically ill controls.

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Estimated Enrollment :	60 participants
Allocation:	Non-Randomized
Intervention Model:	Single Group Assignment
Masking:	None (Open Label)
Primary Purpose:	Treatment
Official Title:	Investigating the Anabolic Response to Resistance Exercise After Critical Illness: The ARTIST-2 Non-Randomized Controlled Trial
Actual Study Start Date :	March 8, 2022
Estimated Primary Completion Date :	March 2023
Estimated Study Completion Date :	March 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Exercise for Older Adults

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Experimental: Former ICU patients Research subjects with a prior history of ICU treatment within six months.	Procedure: Resistance exercise Weighted knee extensions in four sets targeting 8-12 repetitions to failure. Dietary Supplement: Oral protein supplementation 24 grams of hydrolyzed whey protein.
Active Comparator: Age- and sex-matched control group Research subjects without a prior history of ICU treatment within the last 30 years, age- and sex-matched in a 1:2 ratio to the experimental arm.	Procedure: Resistance exercise Weighted knee extensions in four sets targeting 8-12 repetitions to failure. Dietary Supplement: Oral protein supplementation 24 grams of hydrolyzed whey protein.

Outcome Measures

Primary Outcome Measures :

Muscle protein fractional synthetic rate [ Time Frame: 150 minutes post-exercise. ]
The difference between the experimental and active comparator group in muscle protein fractional synthetic rate.

Secondary Outcome Measures :

Gene expression [ Time Frame: 150 minutes post-exercise. ]
The difference between the experimental and active comparator group in gene expression (mRNA) in skeletal muscle, assessed by RNA sequencing.
Signaling pathways [ Time Frame: 150 minutes post-exercise. ]
The difference between the experimental and active comparator group in the activity of major anabolic/catabolic signalining pathways in skeletal muscle, assessed by western blot.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Adult (≥18 years) previously admitted to an ICU at Karolinska University Hospital for ≥3 days and discharged alive from hospital

Adult (≥18 years) without a history of ICU admission within the last 30 years

Exclusion Criteria:

Not able to provide informed consent
>6 months since ICU discharge*
Systemic anticoagulation with LMWH/UFH/DOAC in therapeutic dose range for deep vein thrombosis or pulmonary embolism, or dual antiplatelet therapy
Clinically significant inherited or acquired disorder of hemostasis
Lower-limb amputee
Lower-limb atherosclerotic disease with critical ischemia.
Recent fracture in lower limbs or significant osteoarthritis limiting movement in knee or hip joint
Metastatic cancer or active hematological malignancy
Inherited disorder of amino acid metabolism.
Chronic muscle, neuromuscular or neurologic disease with prior documentation of clinically significant lower-limb involvement
Pregnancy
Single organ failure not requiring invasive mechanical ventilation during ICU stay*

Exclusion criteria marked with asterisk only apply to former ICU patients.

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05261984

Contacts

Layout table for location contacts

Contact: Martin Sundström Rehal, MD PhD	+48-8-58580000	martin.sundstrom@gmail.com
Contact: Arabella Fischer, MD PhD		arabella.fischer@meduniwien.ac.at

Locations

Layout table for location information

Sweden
Karolinska University Hospital	Recruiting
Huddinge, Stockholm, Sweden, 14186
Contact: Martin Sundström Rehal, MD PhD +46-8-58580000 martin.sundstrom@gmail.com

Sponsors and Collaborators

Karolinska University Hospital

Investigators

Layout table for investigator information

Principal Investigator:	Martin Sundström Rehal, MD PhD	Karolinska University Hospital
Study Chair:	Olav Rooyackers, PhD	Karolinska University Hospital

More Information

Publications:

Batt J, Herridge MS, Dos Santos CC. From skeletal muscle weakness to functional outcomes following critical illness: a translational biology perspective. Thorax. 2019 Nov;74(11):1091-1098. doi: 10.1136/thoraxjnl-2016-208312. Epub 2019 Aug 20. Review.

Herridge MS, Tansey CM, Matté A, Tomlinson G, Diaz-Granados N, Cooper A, Guest CB, Mazer CD, Mehta S, Stewart TE, Kudlow P, Cook D, Slutsky AS, Cheung AM; Canadian Critical Care Trials Group. Functional disability 5 years after acute respiratory distress syndrome. N Engl J Med. 2011 Apr 7;364(14):1293-304. doi: 10.1056/NEJMoa1011802.

Plank LD, Connolly AB, Hill GL. Sequential changes in the metabolic response in severely septic patients during the first 23 days after the onset of peritonitis. Ann Surg. 1998 Aug;228(2):146-58.

Puthucheary ZA, Rawal J, McPhail M, Connolly B, Ratnayake G, Chan P, Hopkinson NS, Phadke R, Dew T, Sidhu PS, Velloso C, Seymour J, Agley CC, Selby A, Limb M, Edwards LM, Smith K, Rowlerson A, Rennie MJ, Moxham J, Harridge SD, Hart N, Montgomery HE. Acute skeletal muscle wasting in critical illness. JAMA. 2013 Oct 16;310(15):1591-600. Erratum in: JAMA. 2014 Feb 12;311(6):625. Padhke, Rahul [corrected to Phadke, Rahul].

Wolfe RR. Skeletal muscle protein metabolism and resistance exercise. J Nutr. 2006 Feb;136(2):525S-528S.

Doiron KA, Hoffmann TC, Beller EM. Early intervention (mobilization or active exercise) for critically ill adults in the intensive care unit. Cochrane Database Syst Rev. 2018 Mar 27;3:CD010754. doi: 10.1002/14651858.CD010754.pub2. Review.

Connolly B, Salisbury L, O'Neill B, Geneen L, Douiri A, Grocott MP, Hart N, Walsh TS, Blackwood B; ERACIP Group. Exercise rehabilitation following intensive care unit discharge for recovery from critical illness. Cochrane Database Syst Rev. 2015 Jun 22;(6):CD008632. doi: 10.1002/14651858.CD008632.pub2. Review.

Fossat G, Baudin F, Courtes L, Bobet S, Dupont A, Bretagnol A, Benzekri-Lefèvre D, Kamel T, Muller G, Bercault N, Barbier F, Runge I, Nay MA, Skarzynski M, Mathonnet A, Boulain T. Effect of In-Bed Leg Cycling and Electrical Stimulation of the Quadriceps on Global Muscle Strength in Critically Ill Adults: A Randomized Clinical Trial. JAMA. 2018 Jul 24;320(4):368-378. doi: 10.1001/jama.2018.9592.

Hickmann CE, Castanares-Zapatero D, Deldicque L, Van den Bergh P, Caty G, Robert A, Roeseler J, Francaux M, Laterre PF. Impact of Very Early Physical Therapy During Septic Shock on Skeletal Muscle: A Randomized Controlled Trial. Crit Care Med. 2018 Sep;46(9):1436-1443. doi: 10.1097/CCM.0000000000003263.

Layout table for additonal information

Responsible Party:	Martin Sundstrom Rehal, Principal Investigator, Karolinska University Hospital
ClinicalTrials.gov Identifier:	NCT05261984
Other Study ID Numbers:	K 2022-1113
First Posted:	March 2, 2022 Key Record Dates
Last Update Posted:	June 3, 2022
Last Verified:	June 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:	No

Layout table for additional information

Studies a U.S. FDA-regulated Drug Product:	No
Studies a U.S. FDA-regulated Device Product:	No

Keywords provided by Martin Sundstrom Rehal, Karolinska University Hospital:


Resistance exercise Muscle protein Anabolic resistance

Additional relevant MeSH terms:

Layout table for MeSH terms

Critical Illness Disease Attributes Pathologic Processes

To Top